Search
forLearn
5 / 801 resultslearn Thymosin Beta 4
learn TDM-105795
learn Stem Cell Factor
learn RH410
Research
5 / 1000+ results
research Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers
Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
research CD80CD86 deficiency disrupts regulatory CD4+FoxP3+T cell homoeostasis and induces autoimmune-like alopecia
CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.
research CD4+ Treg expansion arrests disease progression in a pre-clinical model of alopecia areata
Expanding CD4+ Tregs can stop hair loss in alopecia areata.
research Skin CD4+ memory T cells exhibit combined cluster-mediated retention and equilibration with the circulation
Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.
research A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte
A new mouse model effectively mimics vitiligo for research and drug testing.
Community Join
5 / 1000+ resultscommunity Why isn't anyone using Way-316606? If it works then it grows a full head of hair back on most people
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Mallia Aesthetics achieves key regulatory steps for novel sCD83-derived ingredient for hair growth
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.